Circulating Antibody and Memory B-Cell Responses to C. difficile Toxins A and B in Patients with C. difficile-Associated Diarrhoea, Inflammatory Bowel Disease and Cystic Fibrosis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Monaghan, Tanya M ^a   Robins, Adrian ^b   Knox, Alan ^a   Sewell, Herbert F ^b   Mahida, Yashwant R ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; FLUCLOXACILLIN; GENTAMICIN; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; TRIMETHOPRIM;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SECRETING CELL; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; ASYMPTOMATIC INFECTION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; SECRETORY CELL;

ADULT; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; BACTERIAL TOXINS; CELL MOVEMENT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CYSTIC FIBROSIS; DIARRHEA; ENTEROTOXINS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; TIME FACTORS; YOUNG ADULT;

EID: 84883779131     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074452     Document Type: Article

References (30)

1. Monaghan T, Boswell T, Mahida YR, (2008) Recent advances in Clostridium difficile-associated disease. Gut 57: 850-860. PubMed: 18252748.
2. Borriello SP, Barclay FE, (1986) An in-vitro model of colonisation resistance to Clostridium difficile infection. J Med Microbiol 21: 299-309. doi:10.1099/00222615-21-4-299. PubMed: 3723582.
3. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, et al. (2011) Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365: 1693-1703. doi:10.1056/NEJMoa1012413. PubMed: 22047560.
4. Bignardi GE, (1998) Risk factors for Clostridium difficile infection. J Hosp Infect 40: 1-15. doi:10.1016/S0195-6701(98)90182-7. PubMed: 9777516.
5. Kyne L, Warny M, Qamar A, Kelly CP, (2000) Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342: 390-397. doi:10.1056/NEJM200002103420604. PubMed: 10666429.
6. Kyne L, Warny M, Qamar A, Kelly CP, (2001) Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357: 189-193. doi:10.1016/S0140-6736(00)03592-3. PubMed: 11213096.
7. Voth DE, Ballard JD, (2005) Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18: 247-263. doi:10.1128/CMR.18.2.247-263.2005. PubMed: 15831824.
8. Leav BA, Blair B, Leney M, Knauber M, Reilly C, et al. (2010) Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28: 965-969. doi:10.1016/j.vaccine.2009.10.144. PubMed: 19941990.
9. Goodhand JR, Alazawi W, Rampton DS, (2011) Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 33: 428-441. doi:10.1111/j.1365-2036.2010.04548.x. PubMed: 21198703.
10. Peach SL, Borriello SP, Gaya H, Barclay FE, Welch AR, (1986) Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. J Clin Pathol 39: 1013-1018. doi:10.1136/jcp.39.9.1013. PubMed: 3093537.
11. Welkon CJ, Long SS, Thompson CM Jr, Gilligan PH, (1985) Clostridium difficile in patients with cystic fibrosis. Am J Dis Child 139: 805-808. PubMed: 4025261.
12. Johal SS, Hammond J, Solomon K, James PD, Mahida YR, (2004) Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 53: 673-677. doi:10.1136/gut.2003.028803. PubMed: 15082585.
13. Mahida YR, Galvin AM, Gray T, Makh S, McAlindon ME, et al. (1997) Migration of human intestinal lamina propria lymphocytes, macrophages and eosinophils following the loss of surface epithelial cells. Clin Exp Immunol 109: 377-386. doi:10.1046/j.1365-2249.1997.4481346.x. PubMed: 9276536.
14. Modi N, Gulati N, Solomon K, Monaghan T, Robins A, et al. (2011) Differential binding and internalization of Clostridium difficile toxin A by human peripheral blood monocytes, neutrophils and lymphocytes. Scand J Immunol 74: 264-271. doi:10.1111/j.1365-3083.2011.02578.x. PubMed: 21595735.
15. Mahida YR, Galvin A, Makh S, Hyde S, Sanfilippo L, et al. (1998) Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis. Infect Immun 66: 5462-5469. PubMed: 9784558.
16. Kamiya S, Reed PJ, Borriello SP, (1989) Purification and characterisation of Clostridium difficile toxin A by bovine thyroglobulin affinity chromatography and dissociation in denaturing conditions with or without reduction. J Med Microbiol 30: 69-77. doi:10.1099/00222615-30-1-69. PubMed: 2778794.
17. Mullan N, Hughes KR, Mahida YR, (2011) Primary human colonic myofibroblasts are resistant to Clostridium difficile toxin A-induced, but not toxin B-induced, cell death. Infect Immun 79: 1623-1630. doi:10.1128/IAI.00686-10. PubMed: 21245273.
18. Shlomchik MJ, Weisel F, (2012) Germinal center selection and the development of memory B and plasma cells. Immunol Rev 247: 52-63. doi:10.1111/j.1600-065X.2012.01124.x. PubMed: 22500831.
19. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, et al. (1983) Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 148: 93-100. doi:10.1093/infdis/148.1.93. PubMed: 6886489.
20. Warny M, Vaerman JP, Avesani V, Delmée M, (1994) Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 62: 384-389. PubMed: 8300199.
21. McFarland LV, Mulligan ME, Kwok RY, Stamm WE, (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320: 204-210. doi:10.1056/NEJM198901263200402. PubMed: 2911306.
22. Warny M, Pepin J, Fang A, Killgore G, Thompson A, et al. (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366: 1079-1084. doi:10.1016/S0140-6736(05)67420-X. PubMed: 16182895.
23. Johal SS, Solomon K, Dodson S, Borriello SP, Mahida YR, (2004) Differential effects of varying concentrations of clostridium difficile toxin A on epithelial barrier function and expression of cytokines. J Infect Dis 189: 2110-2119. doi:10.1086/386287. PubMed: 15143480.
24. Amanna IJ, Carlson NE, Slifka MK, (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357: 1903-1915. doi:10.1056/NEJMoa066092. PubMed: 17989383.
25. Mekker A, Tchang VS, Haeberli L, Oxenius A, Trkola A, et al. (2012) Immune senescence: relative contributions of age and cytomegalovirus infection. PLOS Pathog 8: e1002850. PubMed: 22916013.
26. Siegrist CA, Aspinall R, (2009) B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 9: 185-194. doi:10.1038/nri2508. PubMed: 19240757.
27. Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, et al. (2009) The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 104: 1162-1169. doi:10.1038/ajg.2009.4. PubMed: 19319128.
28. Mayne CG, Williams CB,. (2013) Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis 19: 1772-1788. PubMed: 23656897.
29. Koon HW, Shih DQ, Hing TC, Yoo JH, Ho S, et al. (2013) Human Monoclonal Antibodies against Clostridium difficile Toxins A and B Inhibit Inflammatory and Histologic Responses to the Toxins in Human Colon and Peripheral Blood Monocytes. Antimicrob Agents Chemother 57: 3214-3223. doi:10.1128/AAC.02633-12. PubMed: 23629713.
30. Kurosaki T, Aiba Y, Kometani K, Moriyama S, Takahashi Y, (2010) Unique properties of memory B cells of different isotypes. Immunol Rev 237: 104-116. doi:10.1111/j.1600-065X.2010.00939.x. PubMed: 20727032.